GBM: Giving Smarter
Glioblastoma Multiforme (GBM) is an aggressive malignant brain tumor involving glial cells of the brain. At the time of this report, nearly 15,000 people were diagnosed with GBM each year in the United States and Europe. The prognosis for GBM patients is very poor, with a median survival time of approximately 14.6 months. Less than 30 percent of patients survive two years after diagnosis.
There are quite a few areas of promising clinical research that could serve as the tipping point toward extending survival in GBM patients and potentially pave the way to a cure. With this report, the Center for Strategic Philanthropy aims to generate awareness and increase funding and participation in medical philanthropy to accelerate the translation of high-impact research into accessible medical solutions to combat GBM.